An­oth­er blue­bird ex­ec jumps ship as ques­tions swirl over gene ther­a­pies and im­mi­nent split

On the same day that their for­mer COO found a new job steer­ing the ship at a biotech fo­cused on en­gi­neer­ing B cells, blue­bird bio said good­bye to an­oth­er C-suite ex­ec­u­tive.

David David­son, blue­bird’s long­time chief med­ical of­fi­cer, is jump­ing ship as ques­tions con­tin­ue to swirl about the safe­ty of their gene ther­a­py pro­grams, the com­pa­ny re­vealed in an SEC fil­ing Tues­day. David­son will leave ef­fec­tive April 16, and will work as a con­sul­tant for six months as blue­bird tran­si­tions to a new CMO. He’ll al­so re­ceive 12 months of sev­er­ance start­ing at the end of April.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER